Zydus Wellness’ First-Ever Stock Split: Tempting At 1:5, But Here’s Why Traders Should Stay Cautious

A consumer firm based in India, Zydus Wellness Limited creates, manufactures, sells, and distributes wellness and health products. Brands including Sugar Free, Everyuth, Nutralite, Glucon-D, and Nycil are among those in their portfolio. The firm announced a stock split for the first time since its founding in an effort to increase access to equity shares and is anticipated to boost involvement from general retail investors.

Zydus Wellness Stock Split

The shareholders at the 31st Annual General meeting (AGM) of the company held on July 30, 2025, have inter-alia approved "Sub-division / split of the existing equity shares of the Company, such that 1 (one) equity share having face value of ₹ 10/- (Rupees Ten only) each fully paid-up, be sub-divided / split into 5 (five) equity shares having face value of ₹ 2/- (Rupees Two only) each fully paid-up, by alteration of Capital Clause of the Memorandum of Association of the Company. The Record Date for sub-division / split of existing equity shares shall be announced separately," said Zydus Wellness in a regulatory filing.

Following the 1:5 split, the number of authorized equity shares will rise from 10 crore to 50 crore, while the authorized share capital would stay at Rs 100 crore. In a similar vein, the total value of the issued, subscribed, and paid-up equity shares will remain at Rs 63.63 crore, but the number of shares will rise from 6,36,32,144 to 31,81,60,720.

Zydus Wellness Q1FY26 Financials

With net sales increasing 2.2% YoY to Rs 857.7 crore from Rs 839.1 crore in Q1 FY25, Zydus Wellness reported a stable performance in Q1 FY26. At Rs 860.9 crore, revenue from operations represented a 2.4% growth. With a gross margin of 54.8% and a minor fall of 73 basis points year on year, the gross contribution climbed marginally to Rs 473.1 crore. Profit before tax (PBT) dropped 4.2% to Rs 145.3 crore, while EBITDA increased 0.2% to Rs 155.6 crore, keeping the margin at 18.1%. At Rs 127.9 crore, profit after tax (PAT) plummeted 13.4% YoY.

Zydus Wellness Target Price

"Zydus Wellness is trading weak, struggling to cross resistance at ₹980. The stock has immediate support at ₹950, and a breakdown below this level could extend losses to ₹930. Momentum indicators remain soft, pointing to limited strength. Any upside will face hurdles near ₹980-₹990. Traders should remain cautious until the price stabilizes above ₹980. Fresh buying is best avoided unless a reversal pattern emerges. Short-term outlook remains negative below ₹950, favoring a wait-and-watch approach," commented Riyank Arora, technical analyst at Mehta Equities.

Disclaimer

The recommendations made above are by market analysts and are not advised by either the author, nor GoodReturns. The author, nor the brokerage firm nor GoodReturns would be liable for any losses caused as a result of decisions based on this write-up. Goodreturns.in advises users to consult with certified experts before making any investment decision.